期刊
CANCER DISCOVERY
卷 10, 期 11, 页码 1672-1689出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-20-0226
关键词
-
类别
资金
- NIH [R01CA227821, P50CA165962]
- NCI Paul Calabresi Career Development Award in Clinical Oncology for Nervous System Tumors [K12CA090354]
- Tawingo Fund
- Richard B. Simches Scholars Award
- Seeman Family MGH Scholar in Neuro-Oncology Award
- Overseas Research Fellowship of the Uehara Memorial Foundation
NAD(+) is an essential cofactor metabolite and is the currency of metabolic transac- tions critical for cell survival. Depending on tissue context and genotype, cancer cells have unique dependencies on NAD(+) metabolic pathways. PARPs catalyze oligomerization of NAD(+) monomers into PAR chains during cellular response to alkylating chemotherapeutics, including procarbazine or temozolomide. Here we find that, in endogenous IDH1-mutant tumor models, alkylator-induced cytotoxicity is markedly augmented by pharmacologic inhibition or genetic knockout of the PAR break-down enzyme PAR glycohydrolase (PARG). Both in vitro and in vivo, we observe that concurrent alkylator and PARG inhibition depletes freely available NAD(+) by preventing PAR breakdown, resulting in NAD(+) sequestration and collapse of metabolic homeostasis. This effect reversed with NAD(+) rescue supplementation, confirming the mechanistic basis of cytotoxicity. Thus, alkylating chemotherapy exposes a genotype-specific metabolic weakness in tumor cells that can be exploited by PARG inactivation. SIGNIFICANCE: Oncogenic mutations in the isocitrate dehydrogenase genes IDH1 or IDH2 initiate diffuse gliomas of younger adulthood. Strategies to maximize the effectiveness of chemotherapy in these tumors are needed. We discover alkylating chemotherapy and concurrent PARG inhibition exploits an intrinsic metabolic weakness within these cancer cells to provide genotype-specific benefit.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据